| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Howe Jolanda | SVP, GLOBAL CONTROLLER | C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY | /s/ Judit Ryvkin, Attorney-in-Fact | 17 Mar 2026 | 0001974200 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Common Stock | Options Exercise | +2,658 | +59% | 7,161 | 15 Mar 2026 | Direct | F1 | ||
| transaction | MIRM | Common Stock | Options Exercise | +6,000 | +84% | 13,161 | 15 Mar 2026 | Direct | F1 | ||
| transaction | MIRM | Common Stock | Sale | $435,239 | -4,732 | -36% | $91.98 | 8,429 | 16 Mar 2026 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Performance Restricted Stock Units | Options Exercise | -2,658 | -100% | $0.000000* | 0 | 15 Mar 2026 | Common Stock | 2,658 | Direct | F1, F3 | ||
| transaction | MIRM | Performance Restricted Stock Units | Options Exercise | -6,000 | -67% | $0.000000* | 3,000 | 15 Mar 2026 | Common Stock | 6,000 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| F2 | Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. |
| F3 | The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. |
| F4 | The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. |